Retatrutide and Tirzepatide are synthetic peptides functioning as dual and triple incretin receptor agonists, respectively, targeting GIP, GLP-1, and in the case of Retatrutide, glucagon receptors. In research settings, they are investigated for their interactions with metabolic regulation pathways, making them subjects of interest in studies on energy homeostasis and glucose response models.